Bio-Rad Laboratories, Inc. BIO is well-poised to grow in the upcoming quarters, courtesy of its strong traction in the QX600 Droplet Digital PCR (ddPCR) platform. Demand for its quality control and ...
BIO benefits from steady Clinical Diagnostics demand and international growth, but macro pressures and currency headwinds ...
The market didn't react positively to the diagnostics specialist's third-quarter earnings report. It beat on both the top and bottom lines, but growth rates were low. Bio-Rad's Q3 saw the company book ...
Bio-Rad stock looks undervalued, boosted by its Sartorius stake, but headwinds and volatile guidance cap upside. Click here ...
Framing Bio-Rad Laboratories after recent performance Bio-Rad Laboratories (BIO) has been under pressure recently, with the ...
Bio-Rad Laboratories, Inc. engages in the development and production of specialty chemicals used in biochemical, pharmaceutical, and other life science research applications. It operates through the ...
Bio-Rad Laboratories, Inc. BIO posted third-quarter 2025 adjusted earnings per share (EPS) of $2.26, which missed the Zacks Consensus Estimate by 1.74%. However, the bottom line increased 11.9% from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results